Home/Filings/4/0001077183-24-000143
4//SEC Filing

Smith Christopher M 4

Accession 0001077183-24-000143

CIK 0001077183other

Filed

Aug 18, 8:00 PM ET

Accepted

Aug 19, 4:19 PM ET

Size

15.9 KB

Accession

0001077183-24-000143

Insider Transaction Report

Form 4
Period: 2024-08-15
Smith Christopher M
Chief Executive Officer
Transactions
  • Tax Payment

    Common Stock

    2024-08-1533,130646,302 total
Holdings
  • Stock Option (Right to Buy)

    Exercise: $19.65Exp: 2030-05-11Common Stock (269,841 underlying)
    269,841
  • Stock Option (Right to Buy)

    Exercise: $16.45Exp: 2034-02-23Common Stock (287,940 underlying)
    287,940
  • Restricted Stock Unit

    Exercise: $0.00Common Stock (172,239 underlying)
    172,239
  • Performance Stock Unit

    Exercise: $0.00From: 2027-02-23Common Stock (172,240 underlying)
    172,240
  • Performance Stock Unit

    Exercise: $0.00From: 2026-05-11Common Stock (144,190 underlying)
    144,190
  • Stock Option (Right to Buy)

    Exercise: $12.62Exp: 2029-08-15Common Stock (694,444 underlying)
    694,444
  • Restricted Stock Unit

    Exercise: $0.00Common Stock (96,127 underlying)
    96,127
Footnotes (9)
  • [F1]Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the August 15, 2024 vesting of restricted stock.
  • [F2]On August 15, 2022, Mr. Smith was granted 694,444 stock options. These options vest ratably over the first four anniversary dates of the grant date.
  • [F3]On May 11, 2023, Mr. Smith was granted 269,841 stock options. These options vest ratably over the first three anniversary dates of the grant date.
  • [F4]On May 11, 2023, Mr. Smith was granted 144,190 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F5]Once vested, the shares of common stock are not subject to expiration.
  • [F6]On May 11, 2023, Mr. Smith was granted 144,190 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 216,285. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.
  • [F7]On February 23, 2024, Mr. Smith was granted 287,940 stock options. These options vest ratably over the first three anniversary dates of the grant date.
  • [F8]On February 23, 2024, Mr. Smith was granted 172,239 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F9]On February 23, 2024, Mr. Smith was granted 172,240 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 258,360. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.

Issuer

NEOGENOMICS INC

CIK 0001077183

Entity typeother

Related Parties

1
  • filerCIK 0001436707

Filing Metadata

Form type
4
Filed
Aug 18, 8:00 PM ET
Accepted
Aug 19, 4:19 PM ET
Size
15.9 KB